Particularly for high-risk patients, rebuilding effective anti-tumor immune responses, such as enhancing memory CD8+ T cell function or regulating specific immune pathway activity, may become important strategies for improving treatment efficacy. This evidence concerns the gene CD8A and neoplasm.